Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 9/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 11/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362381 | 0.80 | P4HTM (1.00) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL564941 | 0.79 | P4HTM (0.82) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL565165 | 0.77 | P4HTM (0.86) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL563745 | 0.76 | P4HTM (0.72) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL4752040 | 0.76 | P4HTM (0.82) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| Hydrochloric Acid SCHEMBL2569110 | 0.75 | P4HTM (0.81) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL4752234 | 0.74 | P4HTM (0.93) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL565127 | 0.73 | P4HTM (0.70) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL564902 | 0.72 | P4HTM (0.73) | P4HTMEGLN2EGLN1EGLN3HIF1AN | |
| SCHEMBL565102 | 0.72 | P4HTM (1.00) | P4HTMEGLN2EGLN1EGLN3HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580778-B2 | Substituted dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | BAYER HARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035151-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE | GLS, ATP6V1B1, PFKP | P4HTM 685/4885EGLN2 301/4885EGLN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.